市场概况

The GvHD treatment market was valued at USD 678.1 百万 2022 预计将达到美元 1,039 百万 2029, 年复合增长率为 6.0%. GvHD occurs when the donor’s T-cells attack the recipient’s healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global GvHD treatment market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, including drug class, treatment type, gender, 和地理.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, 其他的
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males

按地理位置细分
北美 – 美国
欧洲 - 德国, 法国, 英国, 意大利, 西班牙
亚太地区 – 中国, 日本

Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% 到 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.

竞争格局

Key players in the GvHD treatment market include AltruBio, 公司, ASC Therapeutics Inc., 百时美施贵宝公司, Chia Tai-Tianqing Pharmaceutical Holdings Co., 有限公司, Elsalys Biotech SAS, Equillium, 公司, F. 罗氏霍夫曼公司, Genentech, 公司, 葛兰素史克公司, Incyte Corporation, Janssen Global Services, 有限责任公司, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., 有限公司, Kadmon Corporation (赛诺菲公司), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, 公司, Neovii Pharmaceuticals AG, 诺华公司, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, 公司, Takeda Pharmaceutical Company Limited, Xenikos B.V., 除其他外.

报告范围

To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, 地理.
To identify drivers and challenges for the global GvHD treatment market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.

为什么选择这份报告

Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.